Anticancer activity of polyether ionophore-Salinomycin

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 5, 2015, Pages 575-591

  Antoszczak, Michał ^a   Huczyński, Adam ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Anticancer activity; Apoptosis; Cell proliferation; CSC; Polyether ionophores; Sensitizing effect

Indexed keywords

18,19 DIHYDRO 20 DEOXY SALINOMYCIN; 20 DEOXY SALINOMYCIN; CAMPTOTHECIN; CASPASE 3; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; GELATINASE A; GELATINASE B; INOSTAMYCIN; IONOPHORE; LAIDLOMYCIN; LASALOCID; MADURAMICIN; METHOTREXATE; MONENSIN; MULTIDRUG RESISTANCE PROTEIN 1; NARASIN; PACLITAXEL; PODOPHYLLOTOXIN; POLYETHER ANTIBIOTIC AGENT; SALINOMYCIN; SEMDURAMICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; PYRAN DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL PROLIFERATION; DRUG DETERMINATION; DRUG MECHANISM; DRUG SENSITIZATION; DRUG STRUCTURE; EC50; HUMAN; IC50; MODULATION; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; TUMOR REGRESSION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PYRANS;

EID: 84930711810     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150101130209     Document Type: Article

References (123)

1. Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev., 2009, 109, 3012-3043.
2. Bhanot, A.; Sharma, R.; Noolvi, M.N. Natural sources as potential anti-cancer agents: A review. Int. J. Phytomedicine, 2011, 3, 9-26.
3. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
4. Demain, A.L.; Sanchez, S. Microbial drug discovery: 80 years of progress. J. Antibiot., 2009, 62, 5-16.
5. Berdy, J.: Bioactive microbial metabolites. A personal view. J. Antibiot., 2005, 58, 1-26.
6. Dutton, C.J.; Banks, B.J.; Cooper, C.B. Polyether ionophores. Nat. Prod. Rep., 1995, 12, 161-185.
7. Callaway, T.R.; Edrington, T.S.; Rychlik, J.L.; Genovese, K.J.; Poole, T.L.; Jung, Y.S.; Bischoff, K.M.; Anderson, R.C.; Nisbet, D.J. Ionophores: Their use as ruminant growth promotanants and impact on food safety. Curr. Issues Intest. Microbiol., 2003, 4, 43-51.
8. Chapman, H.D.; Barta, J.R.; Blake, D.; Gruber, A.; Jenkins, M.; Smith, N.C.; Suo, X.; Tomley, F.M. A selective review of advances in coccidiosis research. Adv. Parasitol., 2013, 83, 93-171.
9. Kevin D.A.; Meujo, D.A.F.; Hamann, M.T.: Polyether ionophores: Broad spectrum and promising bioactive molecules for the control of drug resistant bacteria and parasites. Exp. Opin. Drug Disc., 2009, 4, 109-146.
10. Rochefeuille, S.; Jimenez, C.; Tingry, S.; Seta, P.; Desfours, J.P.: Mixed Langmuir–Blodgett monolayers containing carboxylic ionophores. Application to Na+ and Ca2+ ISFET-based sensors. Mat. Sci. Eng. C, 2002, 21, 43-46.
11. Gabrielli, C.; Hemery, P.; Letellier, P.; Masure, M.; Perrot, H.; Rahmi, M.I.; Turmine, M.: Investigation of ion-selective electrodes with neutral ionophores and ionic sites by EIS. II. Application to K+ detection. J. Electroanal. Chem., 2004, 570, 291-304.
12. Westley, J.W.: Polyether antibiotics: Versatile carboxylic acid ionophores produced by Streptomyces. Adv. Appl. Microbiol., 1977, 22, 177-223.
13. Mimouni, M.; Khardli, F.Z.; Warad, I.; Ahmad, M.; Mubarak, M.S.; Sultana, S.; Hadda, T.B.: Antimicrobial activity of naturally occurring antibiotics Monensin, Lasalocid and their metal complexes. J. Mater. Environ. Sci., 2014, 5, 207-214.
14. Podila, G.K.; Rosen, E.; San Francisco, M.J.D.; Kolattukudy, P.E. Targeted secretion of cutinase in Fusarium solani f.sp. Pisi and Colletotrichum gloeosporioides. Phytopathology, 1995, 85, 238-242.
15. Cirioni, O.; Giacometti, A.; Barchiesi, F.; Scalise, G.: In-vitro activity of lytic peptides, inhibitors of ion transport systems and ionophorous antibiotics against Pneumocystis carinii. J. Antimicrob. Chemother., 1998, 42, 141-145.
16. Gumila, C.; Ancelin, M.L.; Delort, A.M.; Jeminet, G.; Vial, H.J.: Characterization of the potent in vitro and in vivo antimalarial activities of ionophore compounds. Antimicrob. Agents Chemother., 1997, 41, 523-529.
17. Nakamura, M.; Kunimoto, S.; Takahashi, Y.; Naganawa, H.; Sakaue, M.; Inoue, S.; Ohno, T.; Takeuchi, T. Inhibitory effects of polyethers on human immunodeficiency virus replication. Antimicrob. Agents Chemother., 1992, 36, 492-494.
18. Guyot, J.; Jeminet, G.; Prudhomme, M.; Sancelme, M.; Meiniel, R.: Interaction of the calcium ionophore A. 23187 (Calcimycin) with Bacillus cereus and Escherichia coli. Lett. Appl. Microbial., 1993, 16, 192-195.
19. Imoto, M.; Umezawa, K.; Takahashi, Y.; Naganawa, H.; Iitaka, Y.; Nakamura, H.; Koizumi, Y.; Sasaki, Y.; Hamada, M.; Sawa, T.; Takeuchi, T.: Isolation and structure determination of Inostamycin, a novel inhibitor of phosphatidylinositol turnover. J. Nat. Prod., 1990, 53, 825-829.
20. Kawada, M.; Umezawa, K. Long-lasting accumulation of vinblastine in Inostamycin-treated multidrug-resistant KB cells. JPN. J. Cancer Res., 1991, 83, 1160-1164.
21. Kawada, M.; Umezawa, K. Inostamycin, an inhibitor of P-glycoprotein function, interacts specifically with phosphatidylethanolamine. JPN. J. Cancer Res., 1995, 86, 873-878.
22. Perdue R.E. KB cell culture. I. Role in discovery of antitumor agents from higher plants. J. Nat. Prod., 1982, 45, 418-426.
23. Sharom, F.J. The P-glycoprotein multidrug transporter. Essays Biochem., 2011, 50, 161-178.
24. Imoto, M.; Taniguchi, Y.; Umezawa, K. Inhibition of CDP-DG: Inositol transferase by Inostamycin. J. Biochem., 1992, 112, 299-302.
25. Baba, Y.; Tsukuda, M.; Mochimatsu, I.; Furukawa, S.; Kagata, H.; Nagashima, Y.; Sakai, N.; Koshika, S.; Imoto, M.; Kato, Y. Inostamycin, an inhibitor of cytidine 5’-diphosphate 1,2-diacyl-snglycerol (CDP-DG): Inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and-9 and cell motility in HSC-4 tongue carcinoma cell line. Clin. Exp. Metastasis, 2000, 18, 273-279.
26. Deguchi, A.; Imoto, M.; Umezawa, K. Inhibition of G1 cyclin expression in normal rat kidney cells by Inostamycin, a phosphatidylinositol synthesis inhibitor. J. Biochem., 1996, 120, 1118-1122.
27. Imoto, M.; Tanabe, K.; Simizu, S.; Tashiro, E.; Takada, M.; Umezawa, K. Inhibition of cyclin D1 expression and induction of apoptosis by Inostamycin in small cell lung carcinoma cells. JPN. J. Cancer Res., 1998, 89, 315-322.
28. Hengartner, M.O.; Horvitz, H.R. Programmed cell death in Caenorhabditis elegans. Curr. Opin. Genet. Dev., 1994, 4, 581-586.
29. Baba, Y.; Tsukuda, M.; Mochimatsu, I.; Furukawa, S.; Kagata, H.; Nagashima, Y.; Koshika, S.; Imoto, M.; Kato, Y. Cytostatic effect of Inostamycin, an inhibitor of cytidine 5’-diphosphate 1,2-diacylsn-glycerol (CDP-DG): Inositol transferase, on oral squamous cell carcinoma cell lines. Cell Biol. Int., 2001, 25, 613-620.
30. Baba, Y.; Kato, Y.; Ogawa, K. Inostamycin prevents malignant phenotype of cancer: Inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma. Cell Biol. Int., 2010, 34, 171-175.
31. Simizu, S.; Tanabe, K.; Tashiro, E.; Takada, M.; Umezawa, K.; Imoto, M. Potentiation of Paclitaxel cytotoxicity by Inostamycin in human small cell lung carcinoma. JPN. J. Cancer Res., 1998, 89, 970-976.
32. Yamamoto, K.; Makino, M.; Watanapokasin, R.; Tashiro, E.; Imoto, M. Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface. J. Antibiot., 2012, 65, 295-300.
33. Ozaki, Y.; Matsumoto, Y.; Yatomi, Y.; Higashihara, M.; Kariya, T.; Kume, S. Ionomycin, a Ca++ ionophore, increases platelet volume independently of the Na+ H+ exchanger. Thromb. Res., 1990, 57, 87-95.
34. Park, H.J.; Makepeace, C.M.; Lyons, J.C.; Song, C.W.: Effect of intracellular acidity and Ionomycin on apoptosis in HL-60 cells. Eur. J. Cancer, 1996, 32, 540-546.
35. Miyake, H.; Hara, I.; Yamanaka, K.; Arakawa, S.; Kamidono, S. Calcium ionophor, Ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. J. Urol., 1999, 162, 916-921.
36. Park, C.H.; Hahm, E.R.; Lee, J.H.; Jung, K.C.; Rhee, H.S.; Yang, C.H. Ionomycin downregulates β-catenin/Tcf signaling in colon cancer cell line. Carcinogenesis, 2005, 26, 1929-1933.
37. Gil-Parrado, S.; Fernandez-Montalvan, A.; Assfalg-Machleidt, I.; Popp, O.; Bestvater, F.; Holloschi, A.; Knoch, T.A.; Auerswald, E.A.; Welsh, K.; Reed, J.C.; Fritz, H.; Fuentes-Prior, P.; Spiess, E.; Salvesen, G.S.; Machleidt, W. Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J. Biol. Chem., 2002, 277, 27217-27226.
38. Okamoto, M.; Hara, I.; Miyake, H.; Hara, S.; Gotoh, A.; Arakawa, S.; Kamidono, S. Synergistic antitumor effect of Ionomycin and cisplatin against renal cell carcinoma in vitro and in vivo. J. Urol., 2001, 57, 188-192.
39. Chin, C.S.; Graham, L.J.; Hamad, G.G.; George, K.R.; Bear, H.D. Bryostatin/Ionomycin-activated T cells mediate regression of established tumors. J. Surg. Res., 2001, 98, 108-115.
40. Wang, Y.; Hao, W.; Xing, R.; Di, J.; Zeng, S.; Liu, J.; Xing, F. Ionomycin inhibits Jurkat T cell behaviors in the presence of phorbol-12,13-dibutyrate. Ann. Hematol., 2014, 93, 735-746.
41. Han, S.; Tie, X.; Meng, L.; Wang, Y.; Wu, A. PMA and Ionomycin induce glioblastoma cell death: Activation-induced cell-death-like phenomena occur in glioma cells. PLoS One, 2013, 8, article number e76717.
42. Huczyński, A.; Rutkowski, J.; Wietrzyk, J.; Stefańska, J.; Maj, E.; Ratajczak-Sitarz, M.; Katrusiak, A.; Brzezinski, B.; Bartl, F.: X-ray crystallographic, FT-IR and NMR studies as well as anticancer and antibacterial activity of the salt formed between ionophor antibiotic Lasalocid acid and amines. J. Mol. Struct., 2013, 1032, 69-77.
43. Huczyński, A.; Rutkowski, J.; Borowicz, I.; Wietrzyk, J.; Maj, E.; Brzezinski, B.: One-pot synthesis and cytotoxicity studies of new Mannich base derivatives of polyether antibiotic–Lasalocid acid. Bioorg. Med. Chem. Lett., 2013, 23, 5053-5056.
44. Park, W.H.; Seol, J.G.; Kim, E.S.; Kang, W.K.; Im, Y.H.; Jung, C.W.; Kim, B.K.; Lee, Y.Y.: Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis. Br. J. Haematol., 2002, 119, 400-407.
45. Park, W.H.; Kim, E.S.; Kim, B.K.; Lee, Y.Y.: Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. Int. J. Oncol., 2003, 23, 197-204.
46. Park, W.H.; Kim, E.S.; Jung, C.W.; Kim, B.K.; Lee, Y.Y.: Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle and apoptosis. Int. J. Oncol., 2003, 22, 377-382.
47. Ketola, K.; Vainio, P.; Fey, V.; Kallioniemi, O.; Iljin, K.: Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol. Cancer Ther., 2010, 9, 3175-3185.
48. Sehested, M.; Skovsgaard, T.; Roed, H. The carboxylic ionophore Monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochem. Pharmacol., 1998, 37, 3305-3310.
49. Colombatti, M.; Dell’Arciprete, L.; Chignola, R.; Tridente, G. Carrier protein-Monensin conjugates: Enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res., 1990, 50, 1385-1391.
50. Derbyshire, E.J.; Henry, R.V.; Stahel, R.A.; Wawrzynczak, E.J. Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines. Br. J. Cancer, 1992, 66, 444-451.
51. Ling, Y.; Priebe, W.; Perezsoler, R. Intrinsic cytotoxicity and reversal of multidrug-resistance by Monensin in KB parent and MDR cells. Int. J. Oncol., 1993, 3, 971-977.
52. Wood, D.J.; Rumsby, M.G.; Warr, J.R. Monensin and verapamil do not alter intracellular localization of daunorubicin in multidrug resistant human KB cells. Cancer Lett., 1996, 108, 41-47.
53. Newton, D.L.; Hansen, H.J.; Mikulski, S.M.; Goldenberg, D.M.; Rybak, S.M.: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma. Blood, 2001, 97, 528-535.
54. Singh, M.; Ferdous, A.J.; Jackson, T.L. Stealth Monensin liposomes as a potentiator of adriamycin in cancer treatment. J. Cont. Rel., 1999, 59, 43-53.
55. Singh, M.; Ferdous, A.J.; Kanikkannan, N.; Faulkner, G. Stealth Monensin immunoliposomes as potentiator of immunotoxins in vitro. Eur. J. Pharm. Biopharm., 2001, 52, 13-20.
56. Shaik, M.S.; Jackson, T.L.; Singh, M. Effect of Monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. J. Pharm. Pharmacol., 2003, 55, 819-825.
57. Shaik, M.S.; Chatterjee, A.; Singh, M.: Effects of Monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in Doxorubicin-resistant human breast tumor (MCF-7/dox) cell-line. J. Pharm. Pharmacol., 2004, 56, 899-907.
58. Griffin, T.; Rybak, M.E.; Recht, L.; Singh, M.; Salimi, A.; Raso, V. Potentiation of antitumor immunotoxins by liposomal monensin. J. Natl. Cancer Inst., 1993, 85, 292-298.
59. Yoon, M.J.; Kang, Y.J.; Kim, I.Y.; Kim, E.H.; Lee, J.A.; Lim, J.H.; Kwon, T.K.; Choi, K.S. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis, 2013, 34, 1918-1928.
60. Miyazaki, Y.; Shibuya, M.; Sugawara, H.; Kawaguchi, O.; Hirsoe, C. Salinomycin, a new polyether antibiotic. J. Antibiot., 1974, 27, 814-821.
61. Kocienski, P.J.; Brown, R.C.D.; Pommier, A.; Procter, M. Synthesis of Salinomycin. J. Chem. Soc. Perkin. Trans., 1998, 1, 9-39.
62. Yurkovich, M.E.; Tyrakis, P.A.; Hong, H.; Sun, Y.; Samborskyy, M.; Kamiya, K.; Leadley, P.F. A late-stage intermediate in Salinomycin biosynthesis is revealed by specific mutation in the biosynthetic gene cluster. Chem. Bio. Chem., 2012, 13, 66-71.
63. Naujokat, C.; Fuchs, D.; Opelz, G. Salinomycin in cancer: A new mission for an old agent. Mol. Med. Rep., 2010, 3, 555-559.
64. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009, 138, 645-659.
65. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
66. Arafat, K.; Iratni, R.; Takahashi, T.; Parek, K.; Al Dhaheri, Y.; Adrian, T.E.; Attoub, S. Inhibitory effects of Salinomycin on cell survival, colony growth, migration, and invasion of human nonsmall cell lung cancer A549 and LNM35: Involvement of NAG-1. PLoS One, 2013, 8, e66931.
67. Kim, K.Y.; Yu, S.N.; Lee, S.Y.; Chun, S.S.; Choi, Y.L.; Park, Y.M.; Song, C.S.; Chatterjee, B.; Ahn, S.C.: Salinomycininduced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem. Biophys. Res. Commun., 2011, 413, 80-86.
68. Pulukuri, S.M.; Gondi, C.S.; Lakka, S.S.; Jutla, A.; Estes, N.; Gujrati, M.; Rao, J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem., 2005, 280, 36529-36540.
69. Ketola, K.; Hilvo, M.; Hyotylainen, T.; Vuoristo, A.; Ruskeepaa, A.L.; Oresic, M.; Kallioniemi, O.; Iljin, K.: Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br. J. Cancer, 2012, 106, 99-106.
70. Wu, D.; Zhang, Y.; Huang, J.; Fan, Z.; Shi, F.; Wang, S. Salinomycin inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cell in vitro and suppresses tumor growth in vivo. Biochem. Biophys. Res. Commun., 2014, 443, 712-717.
71. Al Dhaheri, Y.; Attoub, S.; Arafat, K.; Abuqamar, S.; Eid, A.; Al Faresi, N.; Iratni, R.: Salinomycin induces apoptosis and senescence in breast cancer: Upregulation of p21, downregulation of surviving and histone H3 and H4 hyperacetylation. Biochim. Biophys. Acta, 2013, 1830, 3121-3135.
72. Verdoodt, B.; Vogt, M.; Schmitz, I.; Liffers, S.T.; Tannapfel, A.; Mirmohammadsadegh, A. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One, 2012, 7, e44132.
73. Wang, F.; He, L.; Dai, W.Q.; Xu, Y.P.; Wu, D.; Lin, C.L.; Wu, S.M.; Cheng, P.; Zhang, Y.; Shen, M.; Wang, C.F.; Lu, J.; Zhou, Y.Q.; Xu, X.F.; Xu, L.; Guo, C.Y. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One, 2012, 7, e50638.
74. Klose, J.; Stankov, M.V.; Kleine, M.; Ramackers, W.; Panayotova-Dimitrova, D.; Jager, M.D.; Klempnauer, J.; Winkler, M.; Bektas, H.; Behrens, G.M.N.; Vondran, F.W.R. Inhibition of autophagic flux by Salinomycin results in ant-cancer effect in hepatocellular carcinoma cells. PLoS One, 2014, 9, e95970.
75. Koo, K.H.; Kim, H.; Bae, Y.K.; Kim, K.; Park, B.K.; Lee, C.H.; Kim, Y.N. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis., 2013, 4, e693.
76. Zhang, B.; Wang, X.; Cai, F.; Chen, W.; Loesch, U.; Bitzer, J.; Zhong, X.Y. Effects of Salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. Tumor Biol., 2012, 33, 1855-1862.
77. Zhu, L.Q.; Zhen, Y.F.; Zhang, Y.; Guo, Z.X.; Dai, J.; Wang, X.D. Salinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: A negative regulator against cell apoptosis. PLoS One, 2013, 8, e84175.
78. Lieke, T.; Ramackers, W.; Bergmann, S.; Klempnauer, J.; Winkler, M.; Klose, J. Impact of Salinomycin on human cholangiocarcinoma: Induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer, 2012, 12, 466.
79. Fuchs, D.; Heinold, A.; Opelz, G.; Daniel, V.; Naujokat, C.: Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem. Biophys. Res. Commun., 2009, 390, 743-749.
80. Fuchs, D.; Daniel, V.; Sadeghi, M.; Opelz, G.; Naujokat, C.: Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem. Biophys. Res. Commun., 2010, 394, 1098-1104.
81. Lepper, E.R.; Nooter, K.; Verweij, J.; Acharya, M.R.; Figg, W.D.; Sparreboom, A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics, 2005, 6, 115-138.
82. Tiwari, A.K.; Sodani, K.; Dai, C.L.; Ashby, C.R.; Chen, Z.S. Revisting the ABCs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol., 2011, 12, 570-594.
83. Lu, D.; Choi, M.Y.; Yu, J.; Castro, J.E.; Kipps, T.J.; Carson, D.A.: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl. Acad. Sci. USA, 2011, 108, 13253-13257.
84. Dong, T.T.; Zhou, H.M.; Wang, L.L.; Feng, B.; Lv, B.; Zheng, M.H. Salinomycin selectively targets ‘CD133+’ cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann. Surg. Oncol., 2011, 18, 1797-1804.
85. Wang, Y.: Effects of Salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med. Chem., 2011, 7, 106-111.
86. Oak, P.S.; Kopp, F.; Thakur, C.; Ellwart, J.W.; Rapp, U.R.; Ullrich, A.; Wagner, E.; Knyazev, P.; Roidl, A.: Combinational treatment of mammospheres with trastuzumab and Salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int. J. Cancer, 2012, 131, 2808-2819.
87. Zhang, Y.; Zhang, H.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. The eradication of breast cancer and cancer stem cells using octreotide modified Paclitaxel active targeting micelles and Salinomycin passive targeting micelles. Biomaterials, 2012, 33, 679-691.
88. Zhi, Q.M.; Chen, X.H.; Ji, J.; Zhang, J.N.; Li, J.F.; Cai, Q.; Liu, B.Y.; Gu, Q.L.; Zhu, Z.G.; Yu, Y.Y. Salinomycin can effectively kill ALDHhigh stem-like cells on gastric cancer. Biomed. Pharmacother., 2011, 65, 509-515.
89. Kuo, S.Z.; Blair, K.J.; Rahimy, E.; Kiang, A.; Abhold, E.; Fan, J.B.; Wang-Rodriguez, J.; Altuna, X.; Ongkeko, W.M. Salinomycin induces death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer, 2012, 12, 556-570.
90. Tang, Q.L.; Zhao, Z.Q.; Li, J.C.; Liang, Y.; Yin, J.Q.; Zou, C.Y.; Xie, X.B.; Zeng, Y.X.; Shen, J.N.; Kang, T.; Wang, J. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett., 2011, 311, 113-121.
91. Kusunoki, S.; Kato, K.; Tabu, K.; Inagaki, T.; Okabe, H.; Kaneda, H.; Suga, S.; Terao, Y.; Taga, T.; Takeda, S. The inhibitory effect of Salinomycin on the proliferation, migration as well as invasion of human endometrial cancer stem-like cells. Gynecol. Oncol., 2013, 129, 598-605.
92. Park, S.H.; Wang, X.; Liu, R.; Lam, K.S.; Weiss, R.H. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol. Ther., 2008, 7, 2015-2022.
93. Kim, W.K.; Kim, J.H.; Yoon, K.; Kim, S.; Ro, J.; Kang, H.S.; Yoon, S.: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest. New Drugs, 2012, 30, 1311-1318.
94. Idogawa, M.; Sasaki, Y.; Suzuki, H.; Mita, H.; Imai, K.; Shinomura, Y.; Tokino, T.: A single recombinant adenowirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin. Cancer Res., 2009, 15, 3725-3732.
95. Kim, J.H.; Chae, M.J.; Kim, W.K.; Kim, Y.J.; Kang, H.S.; Kim, H.S.; Yoon, S. Salinomycin sensitizes cancer cells to the effects of Doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br. J. Pharmacol., 2011, 162, 773-784.
96. Kim, J.H.; Yoo, H.I.; Kang, H.S.; Ro, J.; Yoon, S. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem. Biophys. Res. Commun., 2012, 418, 98-103.
97. Zhang, G.N.; Liang, Y.; Zhou, L.J.; Chen, S.P.; Chen, G.; Zhang, T.P.; Kang, T.; Zhao, Y.P. Combination of Salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett., 2011, 313, 137-144.
98. Zhou, J.; Li, P.; Xue, X.; He, S.; Kuang, Y.; Zhao, H.; Chen, S.; Zhi, Q.; Guo, X. Salinomycin induces apoptosis in cisplatinresistant colorectal cancer cells by accumulation of reactive oxygen species. Toxic. Lett., 2013, 222, 139-145.
99. Parajuli, B.; Lee, H.G.; Kwon, S.H.; Cha, S.D.; Shin, S.J.; Lee, G.H.; Bae, I.; Cho, C.H. Salinomycin inhibits Akt/NF-ĸB and induces apoptosis in cisplatin resistant ovarian cancer cells. Cancer Epidemiol., 2013, 37, 512-517.
100. Bardsley, M.R.; Horvath, V.J.; Asuzu, D.T.; Lorincz, A.; Redelman, D.; Hayashi, Y.; Popko, L.N.; Young, D.L.; Lomberk, G.A.; Urrutia, R.A.; Farrugia, G.; Rubin, B.P.; Ordog, T. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor α inhibitors in murine gastrointestinal stromal tumors. Gastroenterology, 2010, 139, 942-952.
101. Wang, F.; Dai, W.; Wang, Y.; Shen, M.; Chen, K.; Cheng, P.; Zhang, Y.; Wang, C.; Li, J.; Zheng, Y.; Lu, J.; Yang, J.; Zhu, R.; Zhang, H.; Zhou, Y.; Xu, L.; Guo, C. The synergistic in vitro and in vivo antitumor effect of combination therapy with Salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS One, 2014, 9, e97414.
102. Calzolari, A.; Saulle, E.; De Angelis, M.L.; Pasquini, L.; Boe, A.; Pelacchi, F.; Ricci-Vitiani, L.; Baiocchi, M.; Testa, U. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS One, 2014, 9, e94438.
103. Story, P.; Doube, A. A case of human poisoning by Salinomycin, an agricultural antibiotic. N. Z. Med. J., 2004, 117, U799.
104. Rollinson, J.; Taylor, F.G.R.; Chesney, J. Salinomycin poisoning in horses. Vet. Rec., 1987, 121, 126-128.
105. Lagas, J.S.; Sparidans, R.W.; Van Waterschoot, R.A.B.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H.: P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic Salinomycin. Antimicrob. Agents Chemother., 2008, 52, 1034-1039.
106. Kart, A.; Bilgili, A. Ionophore antibiotics: Toxicity, mode of action and neurotoxic aspects of carboxylic ionophores. J. Anim. Vet. Adv., 2008, 7, 748-751.
107. Dorne, J.L.; Fernandez-Cruz, M.L.; Bertelsen, U.; Renshaw, D.W.; Peltonen, K.; Anadon, A.; Feil, A.; Sanders, P.; Wester, P.; Fink-Gremmels, J. Risk assessment of coccidostatics during feed crosscontamination: Animal and human health aspects. Toxicol. Appl. Pharmacol., 2013, 270, 196-208.
108. Naujokat, C.; Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol., 2012, 950658 950968.
109. Zhang, B.; Wang, X.; Cai, F.; Chen, W.; Loesch, U.; Zhong, X.Y. Antitumor properties of Salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation. Oncol. Rep., 2013, 29, 1371-1378.
110. Hildebrandt, J.; Meingassner, J.G.; Mieth, H. Mode of action of the anticoccidial agent septamycine. Zetralbl. Vet. B, 1978, 25, 186-193.
111. Li, T.; Su, L.; Zhong, N.; Hao, X.; Zhong, D.; Singhal, S.; Liu, X. Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy, 2013, 9, 1057-1068.
112. Riccioni, R.; Dupuis, M.L.; Bernabei, M.; Petrucci, E.; Pasquini, L.; Mariani, G.; Cianfriglia, M.; Testa, U. The cancer stem cell selective inhibitor Salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol. Dis., 2010, 45, 86-92.
113. Reya, T.; Clevers, H. Wnt signaling in stem cells and cancer. Nature, 2005, 434, 843-850.
114. Huczyński, A.; Janczak, J.; Antoszczak, M.; Stefańska, J.; Brzezinski, B. X-ray, FT-IR, NMR and PM5 structural studies and antibacterial activity of unexpectedly stable Salinomycinbenzotriazole intermediate ester. J. Mol. Struct., 2012, 1022, 197-203.
115. Huczyński, A.; Janczak, J.; Stefańska, J.; Antoszczak, M.; Brzezinski, B.: Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-Salinomycin. Bioorg. Med. Chem. Lett., 2012, 22, 4697-4702.
116. Huczyński, A.; Janczak, J.; Antoszczak, M.; Wietrzyk, J.; Maj, E.; Brzezinski, B.: Antiproliferative activity of Salinomycin and its derivatives. Bioorg. Med. Chem. Lett., 2012, 22, 7146-7150.
117. Antoszczak, M.; Maj, E.; Stefańska, J.; Wietrzyk, J.; Janczak, J.; Brzezinski, B.; Huczyński, A.: Synthesis, antiproliferative and antibacterial activity of new amides of Salinomycin. Bioorg. Med. Chem. Lett., 2014, 24, 1724-1729.
118. Antoszczak, M.; Popiel, K.; Stefańska, J.; Wietrzyk, J.; Maj, E.; Janczak, J.; Michalska, G.; Brzezinski, B.; Huczyński, A.: Synthesis, cytotoxicity and antibacterial activity of new esters of polyether antibiotic-Salinomycin. Eur. J. Med. Chem., 2014, 76, 435-444.
119. Borgstrom, B.; Huang, X.; Pošta, M.; Hegardt, C.; Oredsson, S.; Strand, D. Synthetic modification of Salinomycin: Selective Oacylation and biological evaluation. Chem. Commun., 2013, 49, 9944-9946.
120. Huang, X.; Borgstrom, B.; Mansson, L.; Persson, L.; Oredsson, S.; Hegardt, C.; Strand, D. Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified Salinomycin analogues.: ACS Chem. Biol., 2014, 19(7), 1587-1594.
121. Huczyński, A.; Janczak, J.; Łowicki, D.; Brzezinski, B. Monensin a acid complexes as a model of electrogenic transport of sodium cation. Biochim. Biophys. Acta (BBA) Biomembr., 2012, 1818, 2108-2119.
122. Warburg O. On the origin of cancer cells. Science, 1956, 123, 309-314.
123. http://www.who.int/mediacentre/factsheets/fs297/en/ (on-line access: 12.12.2014).